Aronson WJ - Search Results

1

MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer.

Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. Nickols NG, et al. Among authors: aronson wj. Prostate Cancer Prostatic Dis. 2019 Dec;22(4):531-538. doi: 10.1038/s41391-019-0134-5. Epub 2019 Feb 25. Prostate Cancer Prostatic Dis. 2019. PMID: 30804427 Free PMC article.

2

Can we lower the mortality rate of black men with prostate cancer?

Aronson WJ, Freedland SJ. Aronson WJ, et al. J Urol. 2000 Jan;163(1):150-1. J Urol. 2000. PMID: 10604334 No abstract available.

3

Clinical characteristics in black and white men with prostate cancer in an equal access medical center.

Freedland SJ, Sutter ME, Naitoh J, Dorey F, Csathy GS, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Mar;55(3):387-90. doi: 10.1016/s0090-4295(99)00461-6. Urology. 2000. PMID: 10699616

4

Race is not an independent predictor of biochemical recurrence after radical prostatectomy in an equal access medical center.

Freedland SJ, Jalkut M, Dorey F, Sutter ME, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Jul;56(1):87-91. doi: 10.1016/s0090-4295(00)00587-2. Urology. 2000. PMID: 10869631

5

Multivariate analysis of race and adverse pathologic findings after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2000 Nov 1;56(5):807-11. doi: 10.1016/s0090-4295(00)00754-8. Urology. 2000. PMID: 11068307

6

Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy.

Freedland SJ, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2001 Mar;57(3):476-80. doi: 10.1016/s0090-4295(00)01016-5. Urology. 2001. PMID: 11248623

7

Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1016/S0022-5347(01)69076-1. J Urol. 2002. PMID: 11792909

8

Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.

Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. J Urol. 2002 Jul;168(1):110-5. J Urol. 2002. PMID: 12050502

9

Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.

Freedland SJ, Csathy GS, Dorey F, Aronson WJ. Freedland SJ, et al. Among authors: aronson wj. Urology. 2002 Jul;60(1):84-8. doi: 10.1016/s0090-4295(02)01660-6. Urology. 2002. PMID: 12100929

10

Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Freedland SJ, Amling CL, Dorey F, Kane CJ, Presti JC Jr, Terris MK, Aronson WJ; Shared Equal Access Regional Cancer Hospital Database Study Group. Freedland SJ, et al. Among authors: aronson wj. Urology. 2002 Oct;60(4):670-4. doi: 10.1016/s0090-4295(02)01847-2. Urology. 2002. PMID: 12385931

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

282 results

Search Page

Filters